Pegloticase

Alternative Names: KRYSTEXXA

Pegloticase is an intravenous biologic medication used for severe, treatment-refractory chronic gout. It works by converting uric acid into allantoin, a more soluble compound easily excreted by the kidneys. Pegloticase is typically reserved for patients who have failed or cannot tolerate conventional therapies like allopurinol or febuxostat. It is highly effective in rapidly lowering serum uric acid levels and resolving tophi, but carries risks including infusion reactions and development of anti-drug antibodies. Patients are usually pre-medicated and monitored closely during treatment.

Treatment Type: N/A

Treatment Class: N/A

Treatment Modality: N/A

Pegloticase

Review Summary

3.0

1 Reviews

Preferred by 0 Reviewers

Based on the review, Pegloticase is an effective third-line treatment for chronic, refractory gout when standard therapies have failed. However, it comes with serious potential side effects like infusion reactions and anaphylaxis, and is very expensive, requiring careful medical supervision and monitoring.

This summary was generated by users' reviews

Breakdown by Category

Each categories are rated on a 1–5 scale, with 5 being the most favorable outcome and 1 being the least. These scores are averaged across all user reviews to provide a clear sense of how this treatment typically performs in each area.

Cost
1.0
1 = Very Expensive 5 = Very Affordable

1.0

Very Expensive
Relief Speed
2.0
1 = No Relief 5 = Immediate Relief

2.0

Slow Relief
Side Effects
3.0
1 = Intolerable Effect 5 = No Effect

3.0

Moderate Effect
Treatment Line
1.0
1 = Third-line or more 5 = First-line

1.0

Third-line or more

Explore various treatment options to empower yourself in making a well-informed choice.

Choose treatments from the menu above to see how they compare side by side.

Choose treatments from the menu above to see how they compare side by side.

Choose treatments from the menu above to see how they compare side by side.

3.0

1 Reviews
5
0%
4
0%
3
100%
2
0%
1
0%

AI Summary of User Experiences

Not medical advice.

Based on the review, Pegloticase is an effective third-line treatment for chronic, refractory gout when standard therapies have failed. However, it comes with serious potential side effects like infusion reactions and anaphylaxis, and is very expensive, requiring careful medical supervision and monitoring.

Reviews

Filter by reviewer type Pro

Select all Clear all

Cost
Very Expensive
$1000+
Expensive
$501 to $1000
Moderate Cost
$101 to $500
Affordable
$25 to $100
Very Affordable
$25
Relief Speed
No Relief
No noticeable improvement
Slow Relief
Several days to weeks
Moderate Relief
Within 1 - 3 days
Fast Relief
Within hours
Immediate Relief
Within minutes
Side Effect
Intolerable Side Effect
Caused treatment to stop or required hospitalization
Severe Side Effect
Difficult to tolerate, may require intervention
Moderate Side Effect
Noticeable, but manageable
Mild Side Effect
Minor, not bothersome
No Side Effect
Without any adverse effects
Treatment Line
Third-line or more
Used after second-line failed or multiple prior treatment
Second-line
Used after first-line treatment failed or was unsuitable
First-line
First treatment tried
Dr. Curbside

Dr. Curbside

Verified
Physician • Emergency Medicine • How doctors think about decisions — and what real-world experiences add
1 month ago
Pegloticase is a third-line treatment for chronic, refractory gout, used when standard urate-lowering therapies like allopurinol or febuxostat fail or are not tolerated. It is highly effective but can cause serious side effects such as infusion reactions and anaphylaxis, requiring close monitoring and premedication. The treatment is expensive, with costs exceeding $30,000 per month, though financial assistance programs may help offset the price for eligible patients.
#VeryExpensive #SlowRelief #ModerateEffect #Third-lineOrMore #Rescue/EmergencyUse
View Professional Disclosures

Copyright © 2025,Curbside and related marks are registered trademarks of Curbside Tech Inc.

We use cookies to personalize our services and provide you with the best possible experience. By continuing to use this site, you agree to this cookie usage. We also use third-party cookies that help us analyse how you use this website, store your preferences, and provide the content and advertisements that are relevant to you. These cookies will only be stored in your browser with your prior consent. You can learn more about cookies and how your data is processed in the Privacy Policy.

Strictly Necessary Only Accept All